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ABSTRACT 
 
 The authors investigated associations of polymorphism of interleukins genes (-511C/T IL-1B, -889C/T 
IL-1А, VNTR IL-1Ra, C-703T IL-5, T113M IL-9, -592C/A IL-10, -4257G/A IL-13) with nephritic survivance of the ill 
with chronic glomerulonephritis among 238 patients with CGN and 241 control group individuals. It is found 
that genetic variants 2R/5R, 4R/5R VNTR IL-1Ra are associated with accelerated hypotrophy of kidneys. The 
authors revealed factors reducing nephritic survivance. They are alleles -889C IL-1А and -592A IL-10, and 
arterial hypertension during CGN. 
Keywords: chronic glomerulonephritis, accelerated hypotrophy of kidneys, nephritic survivance, genetic 
polymorphism, interleukins. 
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INTRODUCTION 
 
 Nowadays chronic glomerulonephritis (CGN) is a serious problem for modern medical science because 
of disease’s severity and high prevalence rate in different regions of the world [1]. It should be noted that the 
disease involves mainly active working aged persons, and that causes a significant social and economical 
damage [2].     
    
 Chronic glomerulonephritis is an allelically determined immune inflammatory disease [3], for progress 
of which, as shown in the literature, interleukins play an important role [4]. Interleukins genes are very diverse 
from the point of view of population. Some mutations in genes, which code corresponding interleukins, 
substantially change level of their expression, and that can have an impact on the progress of  chronical 
inflammatory process [5].      
 
 Results of works dedicated to investigation of relations between interleukins candidate genes and 
advance of chronic glomerulonephritis are not identical for different populations. As aforesaid, in this work 
you can find estimation of the role of interleukins genetic polymorphisms (-511C/T IL-1B, -889C/T IL-1А, VNTR 
IL-1Ra, C-703T IL-5, T113M IL-9, -592C/A IL-10, -4257G/A IL-13) in accelerated hypotrophy of kidneys of 
patients with chronic glomerulonephritis.   
 
MATERIALS AND METHODS 
 
 Interleukins genes polymorphisms analysis was carried out on the basis of the material of two sample 
groups: 238 patients with chronic glomerulonephritis and 241 control group persons aged 15-79 years old. The 
control group included individuals of Russian ethnicity, born in Central region of Russia and having no blood 
relationship among themselves. Patients were included to the illness group only after disease diagnosis 
ascertainment with the help of clinical and laboratory-instrumental examination technics. Clinical examination 
and diagnostics were performed by workers of  nephrology department of Belgorod regional clinical hospital.          
Exclusionary criteria for the CGN group were diabetes mellitus (in anamnesis or found during the examination), 
hypertensive disease.    
 
Nephritic survivance of persons with CGN was estimated in the group of 138 patients without end-
stage renal disease. Among them 104 patients had unharmed functioning of kidneys (creatinine level was less 
than 140 mcM/l), 34 patients had chronic renal disease (creatinine level was more than 140 mcM/l during 6 
months of observation). For analysis of nephritic survivance and influence of different factors on it we used the 
method of multiplicative estimators of Kaplan-Meier with Cox regression model [6].           
 
We researched 7 polymorphic variants of interleukins genes (-511C/T IL-1B, -889C/T IL-1А, VNTR IL-
1Ra, C-703T IL-5, T113M IL-9, -592C/A IL-10, -4257G/A IL-13), being of great importance for the progress of 
immune inflammatory diseases [7].   
 
DNA was disengaged from peripheral blood via method of phenolic chloroform spirit extraction [8]. 
Analysis of all loci was performed via method of polymerase chain reaction (PCR) of DNA synthesis. Procedures 
and sequences of oligonucleotide primers and probes used are represented in works [9-12]. 
 
DNA markers genotyping was performed via methods of analysis of amplificated fragments lengths 
polymorphism (AFLP) (VNTR IL-1Ra), analysis of restriction fragments lengths polymorphism (-511C/T IL-1B, -
889C/T IL-1А, C-703T IL-5, T113M IL-9, -4257G/A IL-13). 
 
Associations of alleles and genotypes of investigated DNA-markers with speed of chronic 
glomerulonephritis advance were estimated wth the help of analysis of contingency tables 2x2 with calculation 
of criterion 2 with Yates' correction for continuity and odds ratio (OR) with 95% confidence interval (CI). 
Analysis of associations of nephritic survivance with polymorphic genetic markers was performed via method 
of multiplicative estimators of Kaplan-Meier (“STATISTICA 6.0”) [6]. 
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RESULTS 
 
We examined 238 patients with chronic glomerulonephritis and 241 control group persons. Main 
characteristics of examined group of patients with chronic glomerulonephritis and control group are shown in 
table 1. It should be noted that the CGN group level of arterial pressure and creatinine exceeded that of the 
control group (p<0.001). 
During comparative analysis of frequencies of alleles and genotypes of investigated loci of interleukins among 
patients with CGN and the control group we revealed no statistically-valid differences (table 2).      
 
Table 1: Characteristics of the subjects from the case and control groups 
 
Characteristics Cases Controls 
Total 
Males 
Females 
Age, yrs 
Weight, kg 
Height, cm 
SBP, mm Hg 
DBP, mm Hg 
Creatinine, μmol/L 
GFR, ml/min 
238 
127 (53.4%)* 
111 (46.6%)* 
39.58 ± 14.58* 
63.4 ± 2.1* 
165.4 ± 3.4* 
148.4 ± 26.5** 
92.7 ± 14.0** 
337.2 ± 44.1** 
28,2±1,8 
304 
125 (51.86%) 
116 (46.64%) 
42.20 ± 6.28 
67.4 ± 1.7 
168.6 ± 2.7 
128.1 ± 4.4 
82.2 ± 2.0 
130.4 ± 7.8 
81,6±3,4 
Note: *p>0.05; **p<0.001. 
 
Table 2: Summary information about the studied polymorphisms.) 
 
Polymorphism Studied groups Minor allele MAF (%) 
HWE 
χ2 p 
(-511) C/T IL-1B 
(-511) C/T IL-1B 
(-889) C/T IL-1A 
(-889) C/T IL-1A 
VNTR IL-1Ra 
VNTR IL-1Ra 
C-703T IL-5 
C-703T IL-5 
T113M IL-9 
T113M IL-9 
(-592) C/A IL-10 
(-592) C/A IL-10 
(-4257)G/A IL-13 
(-4257)G/A IL-13 
Case 
Control 
Case 
Control 
Case 
Control 
Case 
Control 
Case 
Control 
Case 
Control 
Case 
Control 
(-511)T IL-1B 
(-511)T IL-1B 
(-889)T IL-1A 
(-889)T IL-1A 
IL-1Ra*2 
IL-1Ra*2 
-703T IL-5 
-703T IL-5 
113M IL-9 
113M IL-9 
(-592)A IL-10 
(-592)A IL-10 
(-4257)A IL-13 
(-4257)A IL-13 
33.84 
35.21 
28.03 
32.06 
25.13 
21.84 
25.29 
28.48 
17.66 
18.67 
27.73 
22.67 
27.93 
23.90 
0.01 
0.87 
0.21 
0.89 
0.75 
0.11 
0.10 
0.98 
0.19 
0.36 
0.24 
0.41 
1.53 
0.93 
>0.05 
>0.05 
>0.05 
>0.05 
>0.05 
>0.05 
>0.05 
>0.05 
>0.05 
>0.05 
>0.05 
>0.05 
>0.05 
>0.05 
Notes: MAF, minor allele frequency; HWE, Hardy–Weinberg equilibrium. P values were calculated using the χ
2
 test. 
 
During estimation of nephritic survivance of patients with CGN, depending on genetic polymorphisms 
of interleukins, performed with the help of the method of multiplicative estimators of Kaplan-Meier, we found 
statistically-valid relations with progress speed for a locus IL-1Ra: individuals, which are carriers of genotypes 
2R/5R, 4R/5R, tend to accelerated hypotrophy of kindeys (χ
2
=8.29; p=0.05) (fig. 1). 
 
For identification of factors having unfavourable prognostic value for CGN, we carried out a 
monofactor analysis of nephritic survivance with the help of Cox regression model. It was found that presence 
of allele -889C of gene IL-1А (р=0.05),  allele -592A of gene IL-10 (р=0.05) and arterial hypertension during CGN 
(р=0.01) declines nephritic survivance.  
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Figure 1:  Renal survival of CGN patients with different genotypes of the VNTR polymorphism of the IL-1Ra gene. 
 
SPECULATION 
 
 It was found that carriers of genotypes 2R/5R, 4R/5R VNTR IL-1Ra tend to accelerated hypotrophy of 
kidneys. The question of a functional significance of this polymorphism remains open. It is estimated that 
increase in repeats number promotes transcriptional activity of IL-1Rа. However, most of researches showed 
that decrease in production of IL-1Ra, having anti-inflammatory effect, leads to increase in production of  IL-1B 
with anti-inflammatory effect [11,12]. Thus, this fact explains associations we found: accelerated hypotrophy 
of kidneys with genotypes 2R/5R, 4R/5R VNTR IL-1Ra. 
 
We found factors declining nephritic survivance. Independent factors of risk are carrying of allele -889C of 
gene IL-1А, having anti-inflammatory effect, allele -592A of gene IL-10, having atopic effect, and arterial 
hypertension during CGN. These allelic variants (-889C   IL-1А, -592A IL-10) are являются high-productive [10, 
12, 13] and can cause more express pathogenetic effects of interleukin 10 (atopic effect) and interleukin 1A 
(anti-inflammatory effect) in an organism in the process of CGN advance.   
 
RESUME 
 
Thus, the work’s results allow to judge molecular genetic markers   2R/5R, 4R/5R VNTR IL-1Ra to be 
factors of risk of accelerated hypotrophy of kidney during CGN. Factors declining nephritic survivance are 
carrying of allele  -889C IL-1А,  allele -592A IL-10, arterial hypertension during CGN.  
 
REFERENCES 
 
[1] Pirkle JL, Freedman BI. Minerva Urol Nefrol 2013;65(1):37-50.  
[2] Ekart R, Ferjuc A, Furman B, Gerjevič Š, Bevc S, Hojs R. Ther Apher Dial 2013;17(4):363-7.  
[3] Litovkina O, Nekipelova E, Dvornyk V, Polonikov A, Efremova O, Zhernakova N, Reshetnikov E, 
Churnosov M. Gene 2014;546(1):112-6.  
[4] Deltas C, Pierides A, Voskarides K. Nephrol Dial Transplant 2013;28(12):2946-60.  
[5] Syrjänen J, Hurme M, Lehtimäki T, Mustonen J, Pasternack A. Kidney Int 2002;61(3):1079-85. 
[6] Jager KJ, van Dijk PC, Zoccali C, Dekker FW. Kidney Int 2008;74(5):560-5.  
[7] Mathew CC. Human Press 1984;2:31-34. 
[8] Zhu W, Liu N, Zhao Y, Jia H, Cui B, Ning G. J Endocrinol Invest 2010;33(10):751-5.  
          ISSN: 0975-8585 
September - October 2014  RJPBCS   5(5)  Page No. 1040 
[9] Sehouli J., Mustea A., Koensgen D. et. al. Ann Oncol 2003;14:1501-1504. 
[10] Kim J, Kim Y, Lee KA. World J Gastroenterol 2014;20(16):4558-65.  
[11] Hao L, Li JL, Yue Y, Tian Y, Wang M, Loo WT, Cheung MN, Chow LW, Liu Q, Yip AY, Ng EL. Int J Biol 
Markers 2013;28(1):92-9.  
[12] JS Song, HJ Jeong, SJ Kim. Am J Chin Med 2008;36(1):71-80. 
[13] L Williams, G Jarai, A Smith et al. Leukocyte Biol 2002;72(4):800-809. 
